‘Prototypical’ proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting

References

• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545–558.
   PubMed Web of Science ®Google Scholar
• Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. New Engl J Med Rev. 2018;378:169–180.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97:742–768.
   PubMed Web of Science ®Google Scholar
• Gentile A, Rossi S, Studer V, et al. Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2013;8:651–663.
   PubMed Web of Science ®Google Scholar
• Nandoskar A, Raffel J, Scalfari AS, et al. Pharmacological approaches to the management of secondary progressive multiple sclerosis. Drugs. 2017;77:885–910.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, Van Der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633–652.
   PubMed Web of Science ®Google Scholar
• Paré A, Mailhot B, Lévesque SA, et al. Involvement of the IL-1 system in experimental autoimmune encephalomyelitis and multiple sclerosis: breaking the vicious cycle between IL-1β and GM-CSF. Brain Behav Immun. 2017;62:1–8.
   PubMed Web of Science ®Google Scholar
• Lin -C-C, Edelson BT. New insights into the role of IL-1β in experimental autoimmune encephalomyelitis and multiple sclerosis. J Immunol. 2017;198:4553–4560.
   PubMed Web of Science ®Google Scholar
• Liu X, Quan N. Microglia and CNS interleukin-1: beyond immunological concepts. Front Neurol. 2018;9:8.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Dinarello CA, Molgora M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50:778–795.
   PubMed Web of Science ®Google Scholar
• Netea MG, van de Veerdonk FL, van der Meer JWM, et al. Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol. 2015;33:49–77.
   PubMed Web of Science ®Google Scholar
• O’Neill LAJ. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10–18.
   PubMed Web of Science ®Google Scholar
• Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3(105):cm2.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018;9:1–21.
   PubMed Web of Science ®Google Scholar
• Liu X, Nemeth DP, McKim DB, et al. Cell-type-specific interleukin 1 receptor 1 signaling in the brain regulates distinct neuroimmune activities. Immunity. 2019;50:317–333.
   Web of Science ®Google Scholar
• Qian J, Zhu L, Li Q, et al. Interleukin-1R3 mediates interleukin-1-induced potassium current increase through fast activation of Akt kinase. Proc Natl Acad Sci U S A. 2012;109:12189–12194.
   Web of Science ®Google Scholar
• Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology. 2015;96:70–82.
   PubMed Web of Science ®Google Scholar
• Depino AM, Alonso M, Ferrari C, et al. Learning modulation by endogenous hippocampal IL-1: blockade of endogenous IL-1 facilitates memory formation. Hippocampus. 2004;14:526–535.
   PubMed Web of Science ®Google Scholar
• Goshen I, Kreisel T, Ounallah-Saad H, et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology. 2007;32:1106–1115.
   PubMed Web of Science ®Google Scholar
• Vela JM, Molina-Holgado E, Arévalo-Martín A, et al. Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells. Mol Cell Neurosci. 2002;20:489–502.
   PubMed Web of Science ®Google Scholar
• Xie D, Shen F, He S, et al. IL-1β induces hypomyelination in the periventricular white matter through inhibition of oligodendrocyte progenitor cell maturation via FYN/MEK/ERK signaling pathway in septic neonatal rats. Glia. 2016;64:583–602.
   PubMed Web of Science ®Google Scholar
• Dinčić E, Živković M, Stanković A, et al. Association of polymorphisms in CTLA-4, IL-1ra and IL-1β genes with multiple sclerosis in serbian population. J Neuroimmunol. 2006;177:146–150.
   PubMed Web of Science ®Google Scholar
• Soares JL, Oliveira EM, Pontillo A. Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis. Mult Scler Relat Disord. 2019;29:26–34.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Doolittle TH, Lincoln R, et al. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990;40:1735–1739.
   PubMed Web of Science ®Google Scholar
• Tsukada N, Matsuda M, Miyagi K, et al. Soluble CD4 and CD8 in the peripheral blood of patients with multiple sclerosis and HTLV-1-associated myelopathy. J Neuroimmunol. 1991;35:285–293.
   PubMed Web of Science ®Google Scholar
• Reale M, de Angelis F, di Nicola M, et al. Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients. Int J Mol Sci. 2012;13:12656–12664.
   PubMed Web of Science ®Google Scholar
• Rossi S, Studer V, Motta C, et al. Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflammation. 2014;11:32.
   PubMed Web of Science ®Google Scholar
• Seppi D, Puthenparampil M, Federle L, et al. Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset. J Neuroimmunol. 2014;270:56–60.
   PubMed Web of Science ®Google Scholar
• Rossi S, Furlan R, De Chiara V, et al. Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol. 2012;71:76–83.
   PubMed Web of Science ®Google Scholar
• Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A. 2009;106:4355–4359.
   Web of Science ®Google Scholar
• Mellerård J, Edström M, Vrethem M, et al. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 2010;16:208–217.
   Web of Science ®Google Scholar
• Comabella M, Julià E, Tintoré M, et al. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. J Neurol. 2008;255:1136–1141.
   PubMed Web of Science ®Google Scholar
• Brosnan CF, Cannella B, Battistini L, et al. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology. 1995;45:S16–S21.
   PubMed Web of Science ®Google Scholar
• Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995;37:424–435.
   PubMed Web of Science ®Google Scholar
• McGuinness MC, Powers JM, Bias WB, et al. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J Neuroimmunol. 1997;75:174–182.
   PubMed Web of Science ®Google Scholar
• Van Der Valk P, Amor S. Preactive lesions in multiple sclerosis. Curr Opin Neurol. 2009;22:207–213.
   PubMed Web of Science ®Google Scholar
• Ferrari CC, Depino AM, Prada F, et al. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am J Pathol. 2004;165:1827–1837.
   PubMed Web of Science ®Google Scholar
• Jana M, Pahan K. Redox regulation of cytokine-mediated inhibition of myelin gene expression in human primary oligodendrocytes. Free Radic BiolMed. 2005;39:823–831.
   Web of Science ®Google Scholar
• Burm SM, Peferoen LAN, Zuiderwijk-Sick EA, et al. Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself. J Neuroinflammation. 2016;13:1–16.
   PubMed Web of Science ®Google Scholar
• Heidary M, Rakhshi N, Pahlevan Kakhki M, et al. The analysis of correlation between IL-1B gene expression and genotyping in multiple sclerosis patients. J Neurol Sci. 2014;343:41–45.
   PubMed Web of Science ®Google Scholar
• Peelen E, Damoiseaux J, Muris AH, et al. Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis. Mol Immunol. 2015;63:521–529.
   PubMed Web of Science ®Google Scholar
• Furlan R, Filippi M, Bergami A, et al. Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; A preliminary study. J Neurol Neurosurg Psychiatry. 1999;67:785–788.
   PubMed Web of Science ®Google Scholar
• Duhen T, Campbell DJ. IL-1β promotes the differentiation of polyfunctional human CCR6 + CXCR3 + Th1/17 cells that are specific for pathogenic and commensal microbes. J Immunol. 2014;193:120–129.
   PubMed Web of Science ®Google Scholar
• Sha Y, Markovic-Plese S. Activated IL-1RI signaling pathway induces th17 cell differentiation via interferon regulatory factor 4 signaling in patients with relapsing-remitting multiple sclerosis. Front Immunol. 2016;7:543.
   Web of Science ®Google Scholar
• Calderon TM, Eugenin EA, Lopez L, et al. A role for CXCL12 (SDF-1α) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol. 2006;177:27–39.
   PubMed Web of Science ®Google Scholar
• Mayo L, Trauger SA, Blain M, et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med. 2014;20:1147–1156.
   PubMed Web of Science ®Google Scholar
• Rossi S, Motta C, Studer V, et al. Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Mol Neurodegener. 2014;9:56.
   PubMed Web of Science ®Google Scholar
• Miller SD, Karpus WJ, Davidson TS. Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol. 2010;Chapter15:Unit 15.1.
   PubMedGoogle Scholar
• Schiffenbauer J, Streit WJ, Butfiloski E, et al. The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin Immunol. 2000;95:117–123.
   PubMed Web of Science ®Google Scholar
• Matsuki T, Nakae S, Sudo K, et al. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int Immunol. 2006;18:399–407.
   PubMed Web of Science ®Google Scholar
• Sutton C, Brereton C, Keogh B, et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203:1685–1691.
   PubMed Web of Science ®Google Scholar
• Miranda-Hernandez S, Gerlach N, Fletcher JM, et al. Role for MyD88, TLR2 and TLR9 but not TLR1, TLR4 or TLR6 in experimental autoimmune encephalomyelitis. J Immunol. 2011;187:791–804.
   PubMed Web of Science ®Google Scholar
• Lukens JR, Barr MJ, Chaplin DD, et al. Inflammasome-derived IL-1β regulates the production of GM-CSF by CD4 + T cells and γδ T cells. J Immunol. 2012;188:3107–3115.
   PubMedGoogle Scholar
• Martin D, Near SL. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol. 1995;61:241–245.
   PubMed Web of Science ®Google Scholar
• Jacobs CA, Baker PE, Roux ER, et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1α and suppressed by soluble IL-1 receptor. J Immunol. 1991;146:2983–2989.
   Google Scholar
• Centonze D, Bari M, Rossi S, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain. 2007;130:2543–2553.
   PubMed Web of Science ®Google Scholar
• Mandolesi G, Musella A, Gentile A, et al. Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis. J Neurosci. 2013;33:12105–12121.
   PubMed Web of Science ®Google Scholar
• Aubé B, Lévesque SA, Paré A, et al. Neutrophils mediate blood–spinal cord barrier disruption in demyelinating neuroinflammatory diseases. J Immunol. 2014;193:2438–2454.
   PubMed Web of Science ®Google Scholar
• Baker D, O’Neill JK, Turk JL. Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis. Cell Immunol. 1991;134:505–510.
   PubMed Web of Science ®Google Scholar
• Kennedy MK, Torrance DS, Picha KS, et al. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol. 1992;149:2496–505.
   Google Scholar
• Lévesque SA, Paré A, Mailhot B, et al. Myeloid cell transmigration across the CNS vasculature triggers IL-1ß-driven neuroinflammation during autoimmune encephalomyelitis in mice. J Exp Med. 2016;213:929–949.
   PubMed Web of Science ®Google Scholar
• Ronchi F, Basso C, Preite S, et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells. Nat Commun. 2016;7:11541.
   Web of Science ®Google Scholar
• Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–487.
   PubMed Web of Science ®Google Scholar
• Christy AL, Walker ME, Hessner MJ, et al. Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE. J Autoimmun. 2013;42:50–61.
   PubMed Web of Science ®Google Scholar
• Murphy ÁC, Lalor SJ, Lynch MA, et al. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010;24:641–651.
   PubMed Web of Science ®Google Scholar
• McCandless EE, Budde M, Lees JR, et al. IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis. J Immunol. 2009;183:613–620.
   PubMed Web of Science ®Google Scholar
• Martin BN, Wang C, Zhang CJ, et al. T cell-intrinsic ASC critically promotes T H 17-mediated experimental autoimmune encephalomyelitis. Nat Immunol. 2016;17:583–592.
   Web of Science ®Google Scholar
• Pineau I, Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J Comp Neurol. 2007;500:267–285.
   PubMed Web of Science ®Google Scholar
• Correale J, Farez MF, Cardona AE. The role of astrocytes in multiple sclerosis progression. Front Neurol. 2015;6:1–12.
   PubMed Web of Science ®Google Scholar
• Komuczki J, Tuzlak S, Friebel E, et al. Fate-mapping of GM-CSF expression identifies a discrete subset of inflammation-driving T helper cells regulated by cytokines IL-23 and IL-1beta. Immunity. 2019;50:1289–1304.
   PubMed Web of Science ®Google Scholar
• Argaw AT, Zhang Y, Snyder BJ, et al. IL-1β regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol. 2006;177:5574–5584.
   PubMed Web of Science ®Google Scholar
• Liu X, Yamashita T, Chen Q, et al. Interleukin 1 type 1 receptor restore: A genetic mouse model for studying interleukin 1 receptor-mediated effects in specific cell types. J Neurosci. 2015;35:2860–2870.
   Web of Science ®Google Scholar
• Bruttger J, Karram K, Wörtge S, et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity. 2015;43:92–106.
   PubMed Web of Science ®Google Scholar
• Van Strien ME, Mercier D, Drukarch B, et al. Anti-inflammatory effect by lentiviral-mediated overexpression of IL-10 or IL-1 receptor antagonist in rat glial cells and macrophages. Gene Ther. 2010;17:662–671.
   PubMed Web of Science ®Google Scholar
• Furlan R, Bergami A, Brambilla E, et al. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG35-55-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 2007;14:93–98.
   PubMed Web of Science ®Google Scholar
• Patel J, Balabanov R. Molecular mechanisms of oligodendrocyte injury in multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci. 2012;13:10647–10659.
   PubMed Web of Science ®Google Scholar
• D’Souza SD, Antel JP, Freedman MS. Cytokine induction of heat shock protein expression in human oligodendrocytes: an interleukin-1-mediated mechanism. J Neuroimmunol. 1994;50:17–24.
   PubMed Web of Science ®Google Scholar
• Blasi F, Riccio M, Brogi A, et al. Constitutive expression of interleukin-1β (IL-1β) in rat oligodendrocytes. Biol Chem. 1999;380:259–264.
   Web of Science ®Google Scholar
• Chung IY, Benveniste EN. Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol. 1990;144:2999–3007.
   PubMed Web of Science ®Google Scholar
• Takahashi JL, Giuliani F, Power C, et al. Interleukin-1?? Promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol. 2003;53:588–595.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang J, Wang L, et al. Interleukin-1β impedes oligodendrocyte progenitor cell recruitment and white matter repair following chronic cerebral hypoperfusion. Brain Behav Immun. 2017;60:93–105.
   Web of Science ®Google Scholar
• Mason JL, Suzuki K, Chaplin DD, et al. Interleukin-1β promotes repair of the CNS. J Neurosci. 2001;21:7046–7052.
   Web of Science ®Google Scholar
• Mandolesi G, Gentile A, Musella A, et al. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat Rev Neurol 2015;11:711–724.
   Web of Science ®Google Scholar
• Hewett SJ, Jackman NA, Claycomb RJ. Interleukin-1β in central nervous system injury and repair. Eur J Neurodegener Dis. 2012;1:195–211.
   PubMedGoogle Scholar
• Mandolesi G, De Vito F, Musella A, et al. miR-142-3p is a key regulator of IL-1beta-dependent synaptopathy in neuroinflammation. J Neurosci. 2017;37:546–561.
   PubMed Web of Science ®Google Scholar
• Gentile A, De Vito F, Fresegna D, et al. Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis. Front Cell Neurosci. 2015;9:243.
   Web of Science ®Google Scholar
• Rossi S, Muzio L, De Chiara V, et al. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun. 2011;25:947–956.
   PubMed Web of Science ®Google Scholar
• Di Filippo M, Portaccio E, Mancini A, et al. Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nat Rev Neurosci. 2018;19:599–609.
   PubMed Web of Science ®Google Scholar
• Stampanoni Bassi M, Mori F, Buttari F, et al. Neurophysiology of synaptic functioning in multiple sclerosis. Clin Neurophysiol. 2017;128:1148–1157.
   PubMed Web of Science ®Google Scholar
• Di Filippo M, Chiasserini D, Gardoni F, et al. Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiol Dis. 2013;52:229–236.
   PubMed Web of Science ®Google Scholar
• Nisticò R, Mango D, Mandolesi G, et al. Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLoS One. 2013;8:54666.
   PubMed Web of Science ®Google Scholar
• Mori F, Nisticò R, Mandolesi G, et al. Interleukin-1β promotes long-term potentiation in patients with multiple sclerosis. NeuroMolecular Med. 2014;16:38–51.
   PubMed Web of Science ®Google Scholar
• Gentile A, Fresegna D, Musella A, et al. Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2016;13:231.
   PubMed Web of Science ®Google Scholar
• Gentile A, Fresegna D, Federici M, et al. Dopaminergic dysfunction is associated with IL-1β-dependent mood alterations in experimental autoimmune encephalomyelitis. Neurobiol Dis.2015;74:347–358. cited 2015 Mar 27.
   PubMed Web of Science ®Google Scholar
• Rossi S, Studer V, Motta C, et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology. 2017;89:1338–1347.
   Web of Science ®Google Scholar
• Jordao MJC, Sankowski R, Brendecke SM, et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science. 2019;363:6425.
   Web of Science ®Google Scholar
• Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration. Immunity. 2019;50:955–974.
   PubMed Web of Science ®Google Scholar
• Miron VE, Boyd A, Zhao J-W, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013;16:1211–1218.
   PubMed Web of Science ®Google Scholar
• Dayer JM, Molnarfi N, Burger D. From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation? Expert Opin Biol Ther. 2005;5:S83–S96.
   PubMed Web of Science ®Google Scholar